Distribution of systemic clarithromycin to gingiva

Journal of Periodontology

Volumn 79, Issue 9, 2008, Pages 1712-1718

  Burrell, Renita C ^a   Walters, John D ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Chemotherapy; Inflammation; Macrolides; Periodontitis

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CLARITHROMYCIN;

ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GINGIVA; GINGIVITIS; HUMAN; LONGITUDINAL STUDY; MALE; METABOLISM; PERIODONTICS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SECRETION; TOOTH PLAQUE;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CLARITHROMYCIN; COHORT STUDIES; DENTAL PLAQUE INDEX; FEMALE; FOLLOW-UP STUDIES; GINGIVA; GINGIVAL CREVICULAR FLUID; GINGIVITIS; HUMANS; LONGITUDINAL STUDIES; MALE; PERIODONTAL INDEX; PROSPECTIVE STUDIES;

EID: 51249111993     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.080013     Document Type: Article

References (36)

1. Beikler T, Prior K, Ehmke B, Flemmig TF. Specific antibiotics in the treatment of periodontitis - A proposed strategy. J Periodontol 2004;75:169-175.
2. Slots J. Systemic antibiotics in periodontics. J Periodontol 2004;75:1553-1565.
3. Moore PA. Dental therapeutic indications for the newer long-acting macrolide antibiotics. J Am Dent Assoc 1999;130:1341-1343.
4. Smith SR, Foyle DM, Daniels J, et al. A double-blind placebo-controlled trial of azithromycin as an adjunct to non-surgical treatment of periodontitis in adults: Clinical results. J Clin Periodontol 2002;29: 54-61.
5. Mascarenhas P, Gapski R, Al-Shammari K, et al. Clinical response of azithromycin as an adjunct to non-surgical periodontal therapy in smokers. J Periodontol 2005; 76:426-436.
6. Jain R, Danziger LH. The macrolide antibiotics: A pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 2004;10:3045-3053.
7. Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H. In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1992;36:1241-1243.
8. Pajukanta R. In vitro susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol 1993;8:325-326.
9. Piccolomini R, Catamo G, Di Bonaventura G. Bacteriostatic and bactericidal in vitro activities of clarithromycin and erythromycin against periodontopathic Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 1998;42:3000-3001.
10. Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell K. Activities of telithromycin compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin and other antimicrobial agents against unusual anaerobes. Antimicrob Agents Chemother 1999;43:2801-2805.
11. Merriam CV, Citron DM, Tyrrell KL, Warren YA, Goldstein EJ. In vitro activity of azithromycin and nine comparator agents against 296 strains of oral anaerobes and 31 strains of Elkenella corrodens. Int J Antimicrob Agents 2006;28:244-248.
12. Sefton AM, Maskell JP, Beighton D, et al. Azithromycin in the treatment of periodontal disease. Effect on microbial flora. J Clin Periodontol 1996;23:998-1003.
13. Amsden GW. Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 2001; 18(Suppl 1.):S11-S15.
14. Scaglione F, Demartini G, Dugnani S, Fraschini F. A new model examining intracellular and extracellular activity of amoxicillin, azithromycin, and clarithromycin in infected cells. Chemotherapy 1993;39:416-423.
15. Chou C-H, Walters JD. Clarithromycin transport by gingival fibroblasts and epithelial cells. J Dent Res 2008;87:777-781.
16. AmsdenGW. Anti-inflammatory effects of macrolidesAn underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005;55:10-21.
17. Retsema JA, Bergeron JM, Girard D, Milisen WB, Girard AE. Preferential concentration of azithromycin in an infected mouse thigh model. J Antimicrob Chemother 1993;31(Suppl. E):5-16.
18. Fietta A, Merlini C, Gialdroni Grassi G. Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes. J Chemother 1997;9:23-31.
19. Anderson R, Joone G, van Rensburg CE. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988;22:923-933.
20. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: Possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-282.
21. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991;10:828-833.
22. Ives TJ, Schwab UE, Ward ES, Butts JD, Hall IH. Disposition and functions of clarithromycin in human THP-1 monocytes during stimulated and unstimulated conditions. Res Commun Mol Pathol Pharmacol 2001; 110:183-208.
23. Hall IH, Schwab UE, Ward ES, Butts JD, Wolford ET, Ives TJ. Disposition and intracellular activity of azithromycin in human THP-I acute monocytes. Int J Antimicrob Agents 2002;20:348-360.
24. Gladue RP, Snider ME. Intracellular accumulation of azithromycin by cultured human fibroblasts. Antimicrob Agents Chemother 1990;34:1056-1060.
25. Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence and severity. Acta Odontol Scand 1963; 21:533-551
26. Silness J, Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121-135.
27. Preshaw PM, Kelly PJ, Heasman PA. Quadratic calibration curves for the Periotron 6000. J Periodontal Res 1996;31:441-443.
28. Löe H, Theilade E, Jensen SB. Experimental gingivitis in man. J Periodontol 1965;36:177-187.
29. Sastre Toraño J, Guchelaar HJ. Quantitative determination of the macrolide antibiotics erythromycin, roxithromycin, azithromycin and clarithromycin in human serum by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. J Chromatogr B Biomed Sci Appl 1998; 720:89-97.
30. Blandizzi C, Malizia T, Lupetti A, et al. Periodontal tissue disposition of azithromycin in patients affected by chronic inflammatory periodontal diseases. J Periodontol 1999;70:960-966.
31. Lavda M, Clausnitzer CE, Walters JD. Distribution of systemic ciprofloxacin and doxycycline to gingiva and gingival crevicular fluid. J Periodontal 2004;75:1663-1667.
32. Rodvold KA. Clinical pharmacokinetics of clarithromycin, Clin Pharmacokinet 1999;37:385-398.
33. Zalewska-Kaszubska J, Gorska D. Anti-inflammatory capabilities of macrolides. Pharmacol Res 2001 ;44: 451-454.
34. Gotfried MH. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125:52S-60S.
35. Darany DG, Beck FM, Walters JD. The relationship of gingival fluid leukocyte elastase activity to gingival fluid flow rate. J Periodontol 1992;63:743-747.
36. Mirodzhov GK, Ishankulova DM, Boimatova MB, Negmatova FA. Side effects of Helicobacter pylori eradication therapy (in Russian). Klin Med (Mosk) 2007;85:47-50.